Login / Signup

Pyrimidine-Based Inhibitors of Dynamin I GTPase Activity: Competitive Inhibition at the Pleckstrin Homology Domain.

Luke R OdellMohammed K Abdel-HamidTimothy A HillNgoc ChauKelly A YoungFiona M DeaneJennette A SakoffSofia AnderssonJames A DanielPhillip J RobinsonAdam McCluskey
Published in: Journal of medicinal chemistry (2016)
The large GTPase dynamin mediates membrane fission during clathrin-mediated endocytosis (CME). The aminopyrimidine compounds were reported to disrupt dynamin localization to the plasma membrane via the PH domain and implicate this mechanism in the inhibition of CME. We have used a computational approach of binding site identification, docking, and interaction energy calculations to design and synthesize a new library of aminopyrimidine analogues targeting site-2 of the pleckstrin homology (PH) domain. The optimized analogues showed low micromolar inhibition against both dynamin I (IC50 = 10.6 ± 1.3 to 1.6 ± 0.3 μM) and CME (IC50(CME) = 65.9 ± 7.7 to 3.7 ± 1.1 mM), which makes this series among the more potent inhibitors of dynamin and CME yet reported. In CME and growth inhibition cell-based assays, the data obtained was consistent with dynamin inhibition. CEREP ExpresS profiling identified off-target effects at the cholecystokinin, dopamine D2, histamine H1 and H2, melanocortin, melatonin, muscarinic M1 and M3, neurokinin, opioid KOP and serotonin receptors.
Keyphrases
  • single cell
  • molecular dynamics
  • molecular docking
  • chronic pain
  • pain management
  • electronic health record
  • high throughput
  • cancer therapy
  • drug delivery
  • anti inflammatory
  • density functional theory
  • monte carlo